Illumina traded at $123.84 this Monday March 9th, decreasing $0.78 or 0.63 percent since the previous trading session. Looking back, over the last four weeks, Illumina lost 3.79 percent. Over the last 12 months, its price rose by 44.05 percent. Looking ahead, we forecast Illumina to be priced at 120.86 by the end of this quarter and at 110.23 in one year, according to Trading Economics global macro models projections and analysts expectations.
Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions. The Company operates through segments such as Core Illumina. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Core Illumina consists of its core operations. The Company's portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.